Related references
Note: Only part of the references are listed.Wilms Tumor Gene ( WT1) Peptide- based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer
Sumiyuki Nishida et al.
JOURNAL OF IMMUNOTHERAPY (2014)
Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma
Koichi Shimizu et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer
S. Mitsunaga et al.
BRITISH JOURNAL OF CANCER (2013)
Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer
M. Stotz et al.
BRITISH JOURNAL OF CANCER (2013)
Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients
D. Reyes et al.
BRITISH JOURNAL OF CANCER (2013)
WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial
Takashi Miyatake et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
Hideki Ueno et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer
Masanori Kobayashi et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
An Exploratory Study of Inflammatory Cytokines as Prognostic Biomarkers in Patients With Ductal Pancreatic Adenocarcinoma
Simona O. Dima et al.
PANCREAS (2012)
Clinical and Immunologic Evaluation of Dendritic Cell-Based Immunotherapy in Combination With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma
Yukino Kimura et al.
PANCREAS (2012)
Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches
Osamu Matsuno
RESPIRATORY RESEARCH (2012)
Interleukin-8, a promising predictor for prognosis of pancreatic cancer
Ying Chen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Cancer immunotherapy via dendritic cells
Karolina Palucka et al.
NATURE REVIEWS CANCER (2012)
Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response
Akitaka Takahara et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer
Miho Kaida et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Arginase I-Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes
Paulo C. Rodriguez et al.
CANCER RESEARCH (2009)
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2009)
Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas
J. K. Pine et al.
EJSO (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice
Hanh K. Le et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2009)
Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer
Atsuko Soeda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2009)
Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response
Pratima Sinha et al.
JOURNAL OF IMMUNOLOGY (2007)
Drug-induced lymphocyte stimulation test is not useful for the diagnosis of drug-induced pneumonia
Osamu Matsuno et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Clinical features and correlates of gemcitabine-associated lung injury - Findings from the RADAR project
SM Belknap et al.
CANCER (2006)
Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-γ-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope
M Ohnishi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
E Suzuki et al.
CLINICAL CANCER RESEARCH (2005)
Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome
IJM de Vries et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cancer immunotherapy targeting Wilms' tumor gene WT1 product
H Sugiyama
EXPERT REVIEW OF VACCINES (2005)
Dendritic cell immunotherapy: mapping the way
CG Figdor et al.
NATURE MEDICINE (2004)
Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma
P Hersey et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma
Y Oji et al.
CANCER SCIENCE (2004)
Detection of circulating B cells secreting platelet-specific autoantibody is useful in the diagnosis of autoimmune thrombocytopenia
M Kuwana et al.
AMERICAN JOURNAL OF MEDICINE (2003)
Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues
A Tsuboi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
Share Paper
